M. Lichinitser

4.3k total citations · 1 hit paper
23 papers, 1.3k citations indexed

About

M. Lichinitser is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, M. Lichinitser has authored 23 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in M. Lichinitser's work include Cancer Treatment and Pharmacology (7 papers), Colorectal Cancer Treatments and Studies (5 papers) and HER2/EGFR in Cancer Research (5 papers). M. Lichinitser is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Colorectal Cancer Treatments and Studies (5 papers) and HER2/EGFR in Cancer Research (5 papers). M. Lichinitser collaborates with scholars based in United States, Belgium and Russia. M. Lichinitser's co-authors include S. van der Vegt, J. Mezger, Giuseppe Tonini, Matti Aapro, A. Macciocchi, Christian Peschel, H. P. Sleeboom, Richard J. Gralla, Roberto Labianca and Ilaria Conti and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

M. Lichinitser

23 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

2018 372 citations Yu Jeong Bang, Eduardo Yañez Ruiz et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Lichinitser United States	12	677	623	403	223	146	23	1.3k
Yun-long Pan China	14	222 0.3×	398 0.6×	297 0.7×	148 0.7×	329 2.3×	32	997
Ian D. Schnadig United States	15	199 0.3×	375 0.6×	262 0.7×	209 0.9×	175 1.2×	42	821
Chi‐Young Jeong South Korea	20	393 0.6×	446 0.7×	412 1.0×	111 0.5×	212 1.5×	58	1.1k
Céline Lepère France	15	1.3k 1.9×	258 0.4×	477 1.2×	88 0.4×	147 1.0×	43	1.6k
Yuichiro Miki Japan	23	396 0.6×	464 0.7×	567 1.4×	102 0.5×	311 2.1×	91	1.3k
Ta-Sen Yeh Taiwan	14	538 0.8×	775 1.2×	1.3k 3.2×	66 0.3×	257 1.8×	22	1.8k
Chung‐Wei Fan Taiwan	19	487 0.7×	243 0.4×	141 0.3×	92 0.4×	277 1.9×	41	1.0k
Hsiang‐Lin Tsai Taiwan	20	697 1.0×	440 0.7×	246 0.6×	64 0.3×	380 2.6×	62	1.2k
Peter Grimminger Germany	25	474 0.7×	1.0k 1.6×	1.0k 2.5×	57 0.3×	290 2.0×	131	1.7k
Jeremy French United Kingdom	20	521 0.8×	584 0.9×	337 0.8×	65 0.3×	289 2.0×	63	1.4k

Countries citing papers authored by M. Lichinitser

Since Specialization

Citations

This map shows the geographic impact of M. Lichinitser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Lichinitser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Lichinitser more than expected).

Fields of papers citing papers by M. Lichinitser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Lichinitser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Lichinitser. The network helps show where M. Lichinitser may publish in the future.

Co-authorship network of co-authors of M. Lichinitser

This figure shows the co-authorship network connecting the top 25 collaborators of M. Lichinitser. A scholar is included among the top collaborators of M. Lichinitser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Lichinitser. M. Lichinitser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bang, Yu Jeong, Eduardo Yañez Ruiz, Eric Van Cutsem, et al.. (2018). Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Annals of Oncology. 29(10). 2052–2060. 372 indexed citations breakdown →

Coens, Corneel, Andrew Bottomley, Christian U. Blank, et al.. (2018). Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial: An international randomized double-blind phase III trial. Annals of Oncology. 29. viii456–viii456. 13 indexed citations

Robert, Caroline, Bogusława Karaszewska, Jacob Schachter, et al.. (2014). Combi-V: a Randomised, Open-Label, Phase III Study Comparing the Combination of Dabrafenib (D) and Trametinib (T) with Vemurafenib (V) As First-Line Therapy in Patients (Pts) with Unresectable or Metastatic Braf V600E/K Mutation-Positive Cutaneous Melanoma. Annals of Oncology. 25. v1–v1. 5 indexed citations

Pivot, Xavier, Ann Knoop, Giuseppe Curigliano, et al.. (2012). 445 PrefHer: a Clinical Trial to Evaluate Patient Preference for Trastuzumab Administered Subcutaneously or Intravenously in Patients with HER2-positive Early Breast Cancer. European Journal of Cancer. 48. S176–S176. 2 indexed citations

Gianni, Luca, Gilles Romieu, M. Lichinitser, et al.. (2011). S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2−positive locally recurrent/metastatic breast cancer (LR/mBC). Cancer Research. 71(24_Supplement). S4–8. 29 indexed citations

Wolpin, Brian M., Eileen M. O’Reilly, Y. Ko, et al.. (2011). Global, multicenter, open-label, randomized phase II trial comparing gemcitabine (G) with. G plus AGS-1C4D4 (A) in patients (pts) with metastatic pancreatic cancer (mPC).. Journal of Clinical Oncology. 29(15_suppl). 4031–4031. 8 indexed citations

Yoshida, Ken, K Ikeda, Kunihiro Yoshisue, et al.. (2011). Population pharmacokinetic (PPK) analysis for 5-FU, tegafur (FT), gimeracil (CDHP), and oteracil potassium (Oxo) in the eight clinical studies of S-1 in Western patients with advanced solid tumors.. Journal of Clinical Oncology. 29(4_suppl). 53–53. 4 indexed citations

Bergh, Jonas, Alain Lortholary, Xin Huang, et al.. (2010). Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC).. Journal of Clinical Oncology. 28(18_suppl). LBA1010–LBA1010. 36 indexed citations

Ajani, Jaffer A., G. Bodoky, Vladimir Moiseyenko, et al.. (2009). Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): Secondary and subset analyses. Journal of Clinical Oncology. 27(15_suppl). 4511–4511. 32 indexed citations

10.

Scheithauer, Werner, J Cassidy, Arié Figer, et al.. (2007). A comparison of medical resource use for 4 chemotherapy regimens as first-line treatment for metastatic colorectal cancer (MCRC): XELOX vs. FOLFOX4 ± bevacizumab (A). Journal of Clinical Oncology. 25(18_suppl). 4098–4098. 9 indexed citations

11.

Saltz, Leonard B., Stephen Clarke, Eduardo Díaz‐Rubio, et al.. (2007). Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. Journal of Clinical Oncology. 25(18_suppl). 4028–4028. 83 indexed citations

12.

Untch, Michael, S. Tjulandin, W. Jonat, et al.. (2007). 2108 POSTER Cardiac safety of trastuzumab in combination with epirubicin/ cyclophosphamide as first-line therapy in patients with HER2-positive metastatic breast cancer. European Journal of Cancer Supplements. 5(4). 216–216. 3 indexed citations

13.

Bergström, B., M. Lichinitser, & J.J. Body. (2006). Intravenous and oral ibandronate have better safety and tolerability profiles than zoledronic acid: Evidence from comparative phase III trials. Bone. 38(3). 68–69. 5 indexed citations

14.

Body, J.J., M. Lichinitser, S. Tjulandin, & B. Bergström. (2006). Phase III trial of oral ibandronate and intravenous zoledronic acid in breast cancer patients with bone metastases: comparative bone turnover marker and safety data. European Journal of Cancer Supplements. 4(2). 164–165. 2 indexed citations

15.

Body, J.J., M. Lichinitser, S. Tjulandin, M. Budde, & B. Bergström. (2005). Effect of oral ibandronate versus intravenous (i.v.) zoledronic acid on markers of bone resorption in patients with breast cancer and bone metastases: Results from a comparative phase III trial. Journal of Clinical Oncology. 23(16_suppl). 534–534. 11 indexed citations

16.

Body, Jean‐Jacques, et al.. (2004). Safety of an intravenous (i.v.) dose of ibandronate followed by daily oral dosing in metastatic bone disease: Results of an open-label study. Journal of Clinical Oncology. 22(14_suppl). 735–735. 5 indexed citations

17.

Efficace, Fabio, P. Therasse, M. Piccart, et al.. (2004). Predicting survival with health-related quality of life scores in locally advanced breast cancer: Results from an international randomized controlled trial. Journal of Clinical Oncology. 22(14_suppl). 618–618. 13 indexed citations

18.

Gralla, Richard J., M. Lichinitser, S. van der Vegt, et al.. (2003). Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Annals of Oncology. 14(10). 1570–1577. 367 indexed citations

19.

Belle, Simon Van, M. Lichinitser, Rudolph M. Navari, et al.. (2002). Prevention of cisplatin‐induced acute and delayed emesis by the selective neurokinin‐1 antagonists, L‐758,298 and MK‐869. Cancer. 94(11). 3032–3041. 115 indexed citations

20.

Buzdar, Aman U., Daniel F. Hayes, Shunchao Yan, et al.. (2002). Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast Cancer. Breast Cancer Research and Treatment. 73(2). 161–175. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact